Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Daiichi exits OTC, with $1.55bn unit sale to Suntory

 April 15, 2026

Pharmaphorum

Daiichi Sankyo has agreed to sell its consumer health unit to food and beverage giant Suntory, following a well-trodden path for big pharma companies.

M&A / DealsRead full story

Post navigation

BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut →
← Parkinson’s charity partners Biognosys on biomarker project

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com